TITLE

Estrogen plus progestin reduced risk for fracture in postmenopausal women: COMMENTARY

AUTHOR(S)
Papaioannou, Alexandra
PUB. DATE
May 2004
SOURCE
ACP Journal Club;May/Jun2004, Vol. 140 Issue 3, p61
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The authors, using a global index, confirmed there was no net benefit of estrogen and progestin therapy even in women at high risk for fracture. However, the global index did not include such factors as the risk for dementia and the increase of gynecologic diagnostic procedures because of vaginal bleeding. The risk for probable dementia increased 2-fold in older women allocated to the estrogen and progestin therapy and probably resulted from the increase in vascular dementia. In addition, the number of women requiring diagnostic biopsies increased more than 5-fold among those allocated to combined hormones.
ACCESSION #
13221825

 

Related Articles

  • Change in the use of hormone replacement therapy and the incidence of fracture in Oslo. Meyer, H. E.; Lofthus, C. M.; Søgaard, A. J.; Falch, J. A. // Osteoporosis International;May2009, Vol. 20 Issue 5, p827 

    Fracture incidence in Oslo decreased from the 1970s to the 1990s in younger postmenopausal women, but not in older women or in men. Concurrently, hormone replacement therapy increased considerably. Using data from the Oslo Health Study, we estimated that roughly half the decline might be...

  • Drug company secretly briefed medical societies on HRT. Moynihan, Ray // BMJ: British Medical Journal (International Edition);5/31/2003, Vol. 326 Issue 7400, p1161 

    Reports that the pharmaceutical company Wyeth has admitted that it secretly briefed a number of medical societies about the results of a study into hormone replacement therapy and dementia before they were published. Way that the study shows that the company's combined estrogen and progestogen...

  • Noncardiovascular Outcomes After Hormone Therapy. Huffman, Grace Brooke // American Family Physician;12/1/2002, Vol. 66 Issue 11, p2147 

    Discusses the study 'Noncardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/progestin Replacement Study follow-up,' by S. Hulley et al, from the July 3, 2002 issue of the 'Journal of the American Medical Association.'

  • Cardiovascular Outcomes After Hormone Therapy. Huffman, Grace Brooke // American Family Physician;12/1/2002, Vol. 66 Issue 11, p2155 

    Discusses the study 'Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/progestin Replacement Study follow-up,' by D. Grady et al., from the July 3, 2002 issue of the 'Journal of American Medical Association.'

  • Combined Postmenopausal Hormone Therapy and Cardiovascular Disease: Toward Resolving the Discrepancy between Observational Studies and the Women's Health Initiative Clinical Trial. Prentice, Ross L.; Langer, Robert; Stefanick, Marcia L.; Howard, Barbara V.; Pettinger, Mary; Anderson, Garnet; Barad, David; Curb, J. David; Kotchen, Jane; Kuller, Lewis; Limacher, Marian; Wactawski-Wende, Jean // American Journal of Epidemiology;Sep2005, Vol. 162 Issue 5, p404 

    Observational research on postmenopausal hormone therapy suggests a 40–50% reduction in coronary heart disease incidence among women using these preparations. In contrast, the Women's Health Initiative clinical trial of estrogen plus progestin found an elevated incidence over a 5.6-year...

  • Menopause Hormone Replacement Therapy. King Jr., Frank J. // American Chiropractor;Jun2005, Vol. 27 Issue 6, p56 

    The article reports that commonly prescribed combination drug for hot flashes, containing estrogen and progestin, could decrease heart disease and cancer in women. Just 5 years into the trial, originally planned to run for eight and half years, the women were told to stop taking the hormone...

  • Preventing and Treating Cardiovascular Disease in Women. Nick, Gina L. // Townsend Letter for Doctors & Patients;Nov2004, Issue 256, p34 

    Focuses on the prevention and treatment of cardiovascular disease in women. Hormone replacement therapy; Cardioprotection; Combined conjugated estrogens and progestin; Bioidentical hormone therapy; Relation between intake of whole grain foods and the risk of ischemic stroke among women;...

  • Combined Analysis of Women's Health Initiative Observational and Clinical Trial Data on Postmenopausal Hormone Treatment and Cardiovascular Disease. Prentice, Ross L.; Langer, Robert D.; Stefanick, Marcia L.; Howard, Barbara V.; Pettinger, Mary; Anderson, Garnet L.; Barad, David; Curb, J. David; Kotchen, Jane; Kuller, Lewis; Limacher, Marian; Wactawski-Wende, Jean // American Journal of Epidemiology;Apr2006, Vol. 163 Issue 7, p589 

    Circumstances in which both randomized controlled trial and observational study data are available provide an important opportunity to identify biases and improve study design and analysis procedures. In addition, joint analyses of data from the two sources can extend clinical trial findings....

  • Hormone replacement therapy preparations. Sturdee, David W. // Journal of the British Menopause Society;2000, Vol. 6 Issue 1, p34 

    The article reports on licensed hormone replacement therapy regimens in Great Britain. The most suitable initial treatment for 80 percent of women is oral estrogen. About 15 percent of women have transdermal estrogen. For over 50 years, pellets of crystallized estradiol have been available for...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics